According to FibroGen's latest financial reports the company's current revenue (TTM) is $0.14 B. In 2022 the company made a revenue of $0.14 B a decrease over the years 2021 revenue that were of $0.23 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $0.14 B | 4.99% |
2022 | $0.14 B | -40.19% |
2021 | $0.23 B | 33.46% |
2020 | $0.17 B | -31.28% |
2019 | $0.25 B | 20.48% |
2018 | $0.21 B | 49.16% |
2017 | $0.14 B | -20.5% |
2016 | $0.17 B | -0.69% |
2015 | $0.18 B | 31.41% |
2014 | $0.13 B |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Illumina ILMN | $4.50 B | 2,948.35% | ๐บ๐ธ USA |
Acceleron Pharma XLRN | $0.11 B | -23.68% | ๐บ๐ธ USA |
Accelerate Diagnostics AXDX | $12 M | -91.88% | ๐บ๐ธ USA |